ACET·Nasdaq·US
Adicet Bio
Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company has no approved products and has not yet generated revenue from product sales, relying instead on collaboration and development activity while advancing its cell therapy pipeline.
Recent Activity
Updated Oct 3, 2026
–Adicet Bio's off-the-shelf "gamma delta" CAR-T cell therapy showed early clinical trial evidence of driving lupus into remission.
–The therapy's results surpassed benchmarks previously set by personalized CAR-T treatments tested in lupus.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.